About this trial
The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:
The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.
Eligibility criteria
Qualifiers
cTn>99th ULN or CK-MB>99th ULN
ST-segment elevation with a convex upward morphology
in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings.
cTn>99th ULN or CK-MB>99th ULN
Disqualifiers
Lactating or pregnant women
Patients with malignant neoplasms
Severe hepatic/renal dysfunction
Severe hematological disorders
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Second Affiliated Hospital of Wenzhou Medical University
Lead sponsor
The Central Hospital of Lishui City
Collaborator